Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Athernal Bio receives £700k grant from Innovate UK to expand R&D in targeted immunotherapies for cancer interception.

PRIVATESep 14, 2026•about 3 hours ago

Amount Raised

£700,000

Round Type

Seed

CambridgeBiotechnologyHealth Care

Investors

Delin VenturesInnovate Uk

Description

Athernal Bio, a Cambridge-based immunotherapy company, received a £700k grant through Innovate UK's Growth Catalyst – Investor Partnerships programme. The funding, backed by existing investor Delin Ventures, will support the expansion of operations and R&D efforts. The company develops targeted immunotherapies to treat blood cancer precursor conditions, specifically focusing on high-risk clonal haematopoiesis to prevent progression into acute myeloid leukaemia.

Company Information

Company

Athernal Bio

Location

Cambridge, England, United Kingdom

About

Athernal Bio is developing targeted immunotherapies to treat blood cancer precursor conditions before cancers become established. The company’s primary focus is high-risk clonal haematopoiesis (CH), a widespread cancer precursor condition which can lead to acute myeloid leukaemia and other haematological cancers. High-risk CH affects multiple groups, including patients with rare blood disorders, cancer survivors, and the ageing population. Athernal Bio’s initial programme is an immunotherapy for patients with inherited rare blood disorders, associated with the most aggressive and highly accelerated forms of CH. Athernal Bio has built a strong team, supported by renowned advisors across the US and Europe, to rapidly develop the first therapeutic options for early intervention in patients with high-risk CH, aiming to stop cancer before it starts.

Don't miss Athernal Bio's next move

Get an email the moment Athernal Bio raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Athernal Bio's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Athernal Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.